Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Maximilian Staudt"'
Autor:
Sheng Wang, Sebastian O. Klein, Sylvia Urban, Maximilian Staudt, Nicolas P. F. Barthes, Dominica Willmann, Johannes Bacher, Manuela Sum, Helena Bauer, Ling Peng, Georg A. Rennar, Christian Gratzke, Katrin M. Schüle, Lin Zhang, Oliver Einsle, Holger Greschik, Calum MacLeod, Christopher G. Thomson, Manfred Jung, Eric Metzger, Roland Schüle
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract Inhibition of epigenetic regulators by small molecules is an attractive strategy for cancer treatment. Recently, we characterised the role of lysine methyltransferase 9 (KMT9) in prostate, lung, and colon cancer. Our observation that the enz
Externí odkaz:
https://doaj.org/article/dd0315952e94463cb2a9a88ac996f944
Autor:
Jan-Markus Diederich, Maximilian Staudt, Christian Meisel, Katrin Hahn, Edgar Meinl, Andreas Meisel, Juliane Klehmet
Publikováno v:
Frontiers in Neurology, Vol 9 (2018)
ObjectiveThe objective of this study is to investigate whether chronic inflammatory demyelinating polyneuropathy (CIDP) and its subtypes differ in their type 1 T-helper (TH1) cell response against nodal/paranodal neurofascin (NF186, NF155) as well as
Externí odkaz:
https://doaj.org/article/70fb4453e4f74bcc84682ec5a4e361c5
Autor:
Maximilian Staudt
Publikováno v:
Der Nervenarzt. 94:37-39
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::456d0766a0241f636c8a008abc4d8278
https://doi.org/10.1007/s00115-022-01324-z
https://doi.org/10.1007/s00115-022-01324-z
Autor:
Maximilian, Staudt
Publikováno v:
Der NervenarztLiteratur.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c509edff2741346ac2ce07829d26c909
https://pubmed.ncbi.nlm.nih.gov/35678868
https://pubmed.ncbi.nlm.nih.gov/35678868
Autor:
Manfred Jung, Maximilian Staudt
Publikováno v:
Cell Chemical Biology
Summary Tumor hypoxia is associated with therapy resistance and poor patient prognosis. Hypoxia-activated prodrugs, designed to selectively target hypoxic cells while sparing normal tissue, represent a promising treatment strategy. We report the pre-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::930997ff6420c0865f6d898912ef5142
https://pubmed.ncbi.nlm.nih.gov/33910023
https://pubmed.ncbi.nlm.nih.gov/33910023
Publikováno v:
BMC Neurology
BMC Neurology, Vol 17, Iss 1, Pp 1-7 (2017)
BMC Neurology, Vol 17, Iss 1, Pp 1-7 (2017)
Background Chronic inflammatory demyelinating polyneuropathy (CIDP) is presented by a large heterogeneity of clinical phenotypes. Around 50% of patients suffer from typical CIDP and show better therapy response than atypical variants. The goal of our
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::672653ddd5fb4eea17f14d4aed1c6ef5
https://doi.org/10.1186/s12883-017-0860-z
https://doi.org/10.1186/s12883-017-0860-z
